Biology subjects

Kransdorf, E.

Publications and source records attributed to Kransdorf, E..

3 recordsLinked to original sources

bioRxiv2026

Metabolic niches: MALDI imaging reveals lipidomic heterogeneity in the human heart

The human heart is characterized by aberrant lipid accumulation and remodeling during periods of stress and disease, yet spatially resolved lipidomic profiling of the human heart remains unreported. Here, we employ matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to map lipid distributions across five anatomical regions of healthy human donor hearts (left and right atrium, left and right ventricle, and interventricular septum). Cryosections of donor hearts from healthy subjects were thaw-mounted onto indium tin oxide slides, coated with 2,5-dihydroxyacetophenone, and analyzed on a Bruker timsTOF fleX mass spectrometer in positive and negative ionization modes (50-1850 m/z; 20 m raster). Serial sections were stained with hematoxylin and eosin to enable histological co-registration with lipid distributions. We identified 150 unique lipid species with acyl-chain resolution across four glycerophospholipid classes -- phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylethanolamine (PE), and phosphatidylserine (PS) -- with abundances and spatial distributions differing significantly between regions. H&E co-registration further resolved epicardial and myocardial compartments, enabling tissue-specific lipid mapping. These findings establish the first spatially resolved lipidomic atlas of the human heart and provide a framework for identifying region-specific lipid biomarkers of cardiovascular disease.

Molecular Biology↗

bioRxiv2026

Reductive carboxylation via isocitrate dehydrogenase 1 supports cardiac metabolic adaptation during oncometabolic stress.

BackgroundCardiovascular disease and cancer are the two leading causes of morbidity and mortality worldwide. Metabolic dysregulation of cancer cells extends beyond the tumor microenvironment and increases the risk for cardiovascular diseases. One common somatic mutation in cancer cells affects isocitrate dehydrogenase (IDH) 1 and 2, which catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate in the cytosol and mitochondria, respectively. IDH1 and 2 mutations cause the production of the oncometabolite D-2-hydroxyglutarate (D2-HG), which allosterically inhibits -ketoglutarate dehydrogenase (-KGDH) and is associated with reduced cardiac contractile function. MethodsWe combined stable isotope tracer studies with computational modeling to investigate the fundamental role of IDH isoforms in cardiac adaptation under oncometabolic stress. ResultsWe uncovered an unexpected cardiac phenotype that expands the role of IDH1 in the heart beyond oxidative metabolism. We quantified the stable isotopomer distributions from glucose and glutamine in perfused working rat hearts and isolated adult ventricular cardiomyocytes using mass spectrometry-based metabolomics. Our analysis revealed that defective mitochondrial metabolism causes the redirection of carbon flux from oxidative towards reductive pathways. Reductive carboxylation of -KGDH increases glutamine uptake and glutamine-derived citrate formation in working rat heart perfusions and cultured adult mouse ventricular cardiomyocytes. To identify which IDH isoform is responsible for redirecting carbon flux, we developed knockout models of IDH1, IDH2, and IDH3 in adult mouse ventricular cardiomyocytes. Loss of IDH1 expression impaired the reductive formation of citrate and caused functional defects in cardiomyocytes. Lastly, epigenetic analyses of histone marks revealed that IDH1 induces widespread alterations in histone acetylation and tri-methylation. ConclusionOur results highlight a novel role for IDH1 in cardiac metabolism and transcriptional control of metabolic adaptation to tumor-mediated stress and provide evidence that reductive-citrate formation may induce epigenetic modifications in the heart.

systems biology↗

bioRxiv2019

A precision virtual crossmatch decision support system for interpretation of ambiguous molecular HLA typing data

Virtual crossmatch (VXM) compares a transplant candidates unacceptable antigens to the HLA typing of the donor before an organ offer is accepted and, in selected cases, supplant a prospective physical crossmatch. However, deceased donor typing can be ambiguous, leading to uncertainty in compatibility prediction. We have developed a web application that utilizes ambiguous HLA molecular typing data to assist in VXM assessments. The application compares a candidates listed unacceptable antigens to computed probabilities of all possible two-field donor HLA alleles and UNOS antigens. The VIrtual CrossmaTch for mOleculaR HLA typing (VICTOR) tool can be accessed at http://www.transplanttoolbox.org/victor. We reanalyzed historical VXM cases where a transplant centers manual interpretation of molecular typing results influenced offer evaluation. We found that VICTORs automated interpretation of ambiguous donor molecular typing data would influence VXM decisions. Standardized interpretation of molecular typing data, if applied to the match run, could also change which offers are made. HLA typing ambiguity has been an underappreciated source of immunological risk in organ transplantation. The VICTOR tool can serve as a testbed for development of allocation policies with the aim of decreasing offers refused due to HLA incompatibility.

immunology↗